Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease

Autores
Silber, Ariel Mariano; Coli, Walter; Ulrich, Henning; Manso Alves, Maria; Pereira, Claudio Alejandro
Año de publicación
2005
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Chagas' disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the non-replicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs.
Fil: Silber, Ariel Mariano. Universidade de Sao Paulo; Brasil
Fil: Coli, Walter. Universidade de Sao Paulo; Brasil
Fil: Ulrich, Henning. Universidade de Sao Paulo; Brasil
Fil: Manso Alves, Maria. Universidade de Sao Paulo; Brasil
Fil: Pereira, Claudio Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
AMINO ACID TRANSPORTERS
APTAMERS
ARGININE METABOLISM
CHAGAS' DISEASE
CHEMOTHERAPY
PROLINE METABOLISM
TRYPANOSOMA CRUZI
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/194228

id CONICETDig_41e8c37dbf0e07558a4f4d1b6b111a66
oai_identifier_str oai:ri.conicet.gov.ar:11336/194228
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' diseaseSilber, Ariel MarianoColi, WalterUlrich, HenningManso Alves, MariaPereira, Claudio AlejandroAMINO ACID TRANSPORTERSAPTAMERSARGININE METABOLISMCHAGAS' DISEASECHEMOTHERAPYPROLINE METABOLISMTRYPANOSOMA CRUZIhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Chagas' disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the non-replicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs.Fil: Silber, Ariel Mariano. Universidade de Sao Paulo; BrasilFil: Coli, Walter. Universidade de Sao Paulo; BrasilFil: Ulrich, Henning. Universidade de Sao Paulo; BrasilFil: Manso Alves, Maria. Universidade de Sao Paulo; BrasilFil: Pereira, Claudio Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaBentham Science Publishers Ltd.2005-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/194228Silber, Ariel Mariano; Coli, Walter; Ulrich, Henning; Manso Alves, Maria; Pereira, Claudio Alejandro; Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease; Bentham Science Publishers Ltd.; Current Drug Targets - Infectious Disorders; 5; 1; 12-2005; 53-641568-0053CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.2174/1568005053174636info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/article/35385info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:35:35Zoai:ri.conicet.gov.ar:11336/194228instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:35:35.69CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
title Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
spellingShingle Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
Silber, Ariel Mariano
AMINO ACID TRANSPORTERS
APTAMERS
ARGININE METABOLISM
CHAGAS' DISEASE
CHEMOTHERAPY
PROLINE METABOLISM
TRYPANOSOMA CRUZI
title_short Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
title_full Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
title_fullStr Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
title_full_unstemmed Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
title_sort Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
dc.creator.none.fl_str_mv Silber, Ariel Mariano
Coli, Walter
Ulrich, Henning
Manso Alves, Maria
Pereira, Claudio Alejandro
author Silber, Ariel Mariano
author_facet Silber, Ariel Mariano
Coli, Walter
Ulrich, Henning
Manso Alves, Maria
Pereira, Claudio Alejandro
author_role author
author2 Coli, Walter
Ulrich, Henning
Manso Alves, Maria
Pereira, Claudio Alejandro
author2_role author
author
author
author
dc.subject.none.fl_str_mv AMINO ACID TRANSPORTERS
APTAMERS
ARGININE METABOLISM
CHAGAS' DISEASE
CHEMOTHERAPY
PROLINE METABOLISM
TRYPANOSOMA CRUZI
topic AMINO ACID TRANSPORTERS
APTAMERS
ARGININE METABOLISM
CHAGAS' DISEASE
CHEMOTHERAPY
PROLINE METABOLISM
TRYPANOSOMA CRUZI
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Chagas' disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the non-replicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs.
Fil: Silber, Ariel Mariano. Universidade de Sao Paulo; Brasil
Fil: Coli, Walter. Universidade de Sao Paulo; Brasil
Fil: Ulrich, Henning. Universidade de Sao Paulo; Brasil
Fil: Manso Alves, Maria. Universidade de Sao Paulo; Brasil
Fil: Pereira, Claudio Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Chagas' disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the non-replicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs.
publishDate 2005
dc.date.none.fl_str_mv 2005-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/194228
Silber, Ariel Mariano; Coli, Walter; Ulrich, Henning; Manso Alves, Maria; Pereira, Claudio Alejandro; Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease; Bentham Science Publishers Ltd.; Current Drug Targets - Infectious Disorders; 5; 1; 12-2005; 53-64
1568-0053
CONICET Digital
CONICET
url http://hdl.handle.net/11336/194228
identifier_str_mv Silber, Ariel Mariano; Coli, Walter; Ulrich, Henning; Manso Alves, Maria; Pereira, Claudio Alejandro; Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease; Bentham Science Publishers Ltd.; Current Drug Targets - Infectious Disorders; 5; 1; 12-2005; 53-64
1568-0053
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.2174/1568005053174636
info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/article/35385
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers Ltd.
publisher.none.fl_str_mv Bentham Science Publishers Ltd.
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614374615941120
score 13.070432